Greenlight Capital's Q2 Trades: New Positions in FLR, VSCO, and Exit from VTRS
ByAinvest
Thursday, Aug 14, 2025 12:14 pm ET1min read
FLR--
Greenlight Capital acquired 760.6K shares of Fluor and 168.3K shares of Victoria's Secret during the second quarter of 2025, according to the latest 13F filing [1]. The firm also sold its entire position in Varex Imaging, which had been part of its portfolio. Other significant trades include increasing its stake in Albireo Pharma and Amgen, and reducing its holdings in Activision Blizzard and Bristol Myers Squibb.
Separately, the SEC filing form 4 reveals that Thomas James Curnock, the Group Chief Underwriting Officer at Greenlight Capital Re, Ltd., sold 11,500 ordinary shares on August 8, 2025, at a price of $12.9345 per share, totaling $148,746 [2].
These moves by Greenlight Capital reflect the hedge fund's strategy and positioning in various sectors. Investors should closely monitor these developments to understand the fund's approach and potential future investments.
References:
[1] https://seekingalpha.com/news/4485554-david-einhorns-greenlight-capital-adds-flr-vsco-exits-vtrs-among-other-trades
[2] https://www.tradingview.com/news/tradingview:0ce9c15714637:0-greenlight-capital-re-executive-sells-shares/
VSCO--
David Einhorn's Greenlight Capital has disclosed its Q2 2025 13F filing, revealing new positions in Fluor (760.6K shares) and Victoria's Secret (168.3K shares). The hedge fund also exited its position in Varex Imaging (VTRS). Other notable trades include adding to existing positions in Albireo Pharma (ABIO), Amgen (AMGN), and reducing holdings in Activision Blizzard (ATVI) and Bristol Myers Squibb (BMY).
David Einhorn's Greenlight Capital has released its Q2 2025 13F filing, providing insights into the hedge fund's latest investment activities. The filing indicates that Greenlight Capital has taken new positions in Fluor (NYSE:FLR) and Victoria's Secret (NYSE:VSCO), while also exiting its position in Varex Imaging (VTRS). Additionally, the fund has made other notable trades, including adding to existing positions in Albireo Pharma (ABIO), Amgen (AMGN), and reducing holdings in Activision Blizzard (ATVI) and Bristol Myers Squibb (BMY).Greenlight Capital acquired 760.6K shares of Fluor and 168.3K shares of Victoria's Secret during the second quarter of 2025, according to the latest 13F filing [1]. The firm also sold its entire position in Varex Imaging, which had been part of its portfolio. Other significant trades include increasing its stake in Albireo Pharma and Amgen, and reducing its holdings in Activision Blizzard and Bristol Myers Squibb.
Separately, the SEC filing form 4 reveals that Thomas James Curnock, the Group Chief Underwriting Officer at Greenlight Capital Re, Ltd., sold 11,500 ordinary shares on August 8, 2025, at a price of $12.9345 per share, totaling $148,746 [2].
These moves by Greenlight Capital reflect the hedge fund's strategy and positioning in various sectors. Investors should closely monitor these developments to understand the fund's approach and potential future investments.
References:
[1] https://seekingalpha.com/news/4485554-david-einhorns-greenlight-capital-adds-flr-vsco-exits-vtrs-among-other-trades
[2] https://www.tradingview.com/news/tradingview:0ce9c15714637:0-greenlight-capital-re-executive-sells-shares/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet